Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Genuit Group Plc LSE:GEN London Ordinary Share GB00BKRC5K31 ORD GBP0.001
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 271.00 271.00 271.50 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Industrial Engineering 594.3 62.9 16.7 16.2 673

Genmab A/S Genmab Improves Its 2021 Financial Guidance

04/11/2021 8:24pm

UK Regulatory (RNS & others)


 
TIDMGEN 
 

Company Announcement

   -- Genmab improves its 2021 financial guidance 

COPENHAGEN, Denmark; November 4, 2021 -- https://www.globenewswire.com/Tracker?data=ZC4U2HcsfcZuwyf5e-wMniLHvlXSFLoG3XlurG2571yJvAl61nb2qmXdNTCcmVmskgdnaIeeSerWy7xfDfo6WA== Genmab A/S (Nasdaq: GMAB) announced today that it is improving its 2021 financial guidance published on August 11, 2021. The improved guidance is driven primarily by increased royalty revenue related to the net sales of DARZALEX(R) (daratumumab), both intravenous and subcutaneous formulations, and lower operating expense resulting from timing of investments for R&D activities and organizational capability build.

Genmab's projected revenue for 2021 primarily consists of DARZALEX royalties. Such royalties are based on Genmab's revised estimate of DARZALEX 2021 net sales of USD 5.9--6.2 billion compared to Genmab's previous estimate of USD 5.6-5.9 billion.

 
 
                             Revised           Previous 
  (DKK million)             Guidance           Guidance 
--------------------- 
  Revenue                   7,900 - 8,500      7,300 - 7,900 
  Operating expenses    (5,300) - (5,600)  (5,500) - (5,800) 
  Operating result          2,300 - 3,200      1,500 - 2,400 
 

Genmab's financial results for the first nine months of 2021 will be published on November 10, 2021.

The above expectations are based on assumptions including those described on pages 5 and 6 of the Interim Report for the First Half of 2021 (Company Announcement No. 60 / 2021).

About Genmab

Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. For more than 20 years, Genmab's vision to transform cancer treatment has driven its passionate, innovative and collaborative teams to invent next-generation antibody technology platforms and leverage translational research and data sciences, fueling multiple differentiated cancer treatments that make an impact on people's lives. To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab's proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.

Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com https://www.globenewswire.com/Tracker?data=ZC4U2HcsfcZuwyf5e-wMnqTe9HJvdBbcUp3-yHh_7r4oY082N6sPZsQwV_hcmeWMLbyR91yg8LrzuUMKKdKZu9Tu65TIlKvF_bsICFwB7A9dGdXwafVdeukXlH53YEsfxbflrMSORE9oroPLFOr7ZQ== and follow us on Twitter.com/Genmab https://www.globenewswire.com/Tracker?data=LFwqlCw8urFjq5xBTrTJQQ2nuBznlo-Xz2i7e6aNUnyBth-JySwR5m1gRW__rIFcmQKncGOkz1WUktWTDpAIhNCbu4u4ljnePu0uXvVoyBk= .

Contact:

Marisol Peron, Senior Vice President, Global Investor Relations & Communications

T: +1 609 524 0065; E: mmp@genmab.com https://www.globenewswire.com/Tracker?data=BJEWaUUdhLcjxzAwcXFRO0pIeTe3bI8Dx2wZgPLUUrpwNCL20tzPi9igF5Ijvz_wAcfczbIxclYAxj0sqbZ7DA==

For Investor Relations:

Andrew Carlsen, Vice President, Head of Investor Relations

T: +45 3377 9558; E: acn@genmab.com https://www.globenewswire.com/Tracker?data=VlrSJIIIyR766aL8zqgnYBDwVaMeazx8R9RYcLzpMLMzbXZWi4CXz336qppFRvDNJeaAYPPljDYKh4iECv5s7g==

This Company Announcement contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on https://www.globenewswire.com/Tracker?data=EUNsGSmLikh77wJbIWFY0DvX9dmqaCLr0pTjcSngk6XTbQC93Mhm9QuVxq7BEg1DbbfRymUteJ2qOP4h05GE7g== www.genmab.com and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at https://www.globenewswire.com/Tracker?data=EUNsGSmLikh77wJbIWFY0ECWHr7CxPU9LuE-S8PU0lVLJ3u9RDBFF0hRfot_r0ACpSC617YarWxL_fqC8fV8qCEtsHvKFf3JDtC-vtikW6s= www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab(R) ; the Y-shaped Genmab logo(R) ; Genmab in combination with the Y-shaped Genmab logo(R) ; HuMax(R) ; DuoBody(R) ; DuoBody in combination with the DuoBody logo(R) ; HexaBody(R) ; HexaBody in combination with the HexaBody logo(R) ; DuoHexaBody(R) and HexElect(R) . DARZALEX(R) is a trademark of Johnson & Johnson.

Company Announcement no. 66

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

Attachment

   -- 041121_CA66_Financial Guidance Update 
      https://ml-eu.globenewswire.com/Resource/Download/0242e84e-84b3-4d61-84ee-fe33d58d7b3f 
 
 
 

(END) Dow Jones Newswires

November 04, 2021 16:24 ET (20:24 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

1 Year Genuit Chart

1 Year Genuit Chart

1 Month Genuit Chart

1 Month Genuit Chart
ADVFN Advertorial
Your Recent History
LSE
GEN
Genuit
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220930 06:00:15